Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 28, Issue 11, Pages 2353-2363
Publisher
Springer Science and Business Media LLC
Online
2022-11-11
DOI
10.1038/s41591-022-02047-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition
- (2022) Bob T. Li et al. NATURE MEDICINE
- Liquid biopsy enters the clinic — implementation issues and future challenges
- (2021) Michail Ignatiadis et al. Nature Reviews Clinical Oncology
- Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
- (2021) Mahrukh M Syeda et al. LANCET ONCOLOGY
- Liquid Biopsy: From Discovery to Clinical Application
- (2021) Catherine Alix-Panabières et al. Cancer Discovery
- Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).
- (2021) Debora S. Bruno et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.
- (2021) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
- (2021) A. Rose Brannon et al. Nature Communications
- Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
- (2021) Christian Rolfo et al. Journal of Thoracic Oncology
- Clonal hematopoiesis is associated with risk of severe Covid-19
- (2021) Kelly L. Bolton et al. Nature Communications
- Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC)
- (2020) Aaron C. Tan Thoracic Cancer
- Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
- (2020) Philip C. Mack et al. CANCER
- Speeding tumor genotyping during the SARS‐CoV‐2 outbreak through liquid biopsy
- (2020) Christian Rolfo et al. CANCER
- Integrating genomic features for non-invasive early lung cancer detection
- (2020) Jacob J. Chabon et al. NATURE
- The mutational constraint spectrum quantified from variation in 141,456 humans
- (2020) Konrad J. Karczewski et al. NATURE
- Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
- (2020) Anne Marie Lennon et al. SCIENCE
- Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
- (2020) Andrew J. Piper-Vallillo et al. JOURNAL OF CLINICAL ONCOLOGY
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- Older adult participation in cancer clinical trials: A systematic review of barriers and interventions
- (2020) Mina S. Sedrak et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
- (2020) Barzin Y. Nabet et al. CELL
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
- (2020) Nicholas C Turner et al. LANCET ONCOLOGY
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis
- (2020) Kelly L. Bolton et al. NATURE GENETICS
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
- (2020) Yoshiaki Nakamura et al. NATURE MEDICINE
- Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
- (2019) B T Li et al. ANNALS OF ONCOLOGY
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- (2019) Natasha B. Leighl et al. CLINICAL CANCER RESEARCH
- Genome-wide cell-free DNA fragmentation in patients with cancer
- (2019) Stephen Cristiano et al. NATURE
- Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
- (2019) Dominic G. Rothwell et al. NATURE MEDICINE
- Optimization of Population Frequency Cutoffs for Filtering Common Germline Polymorphisms from Tumor-Only Next-Generation Sequencing Data
- (2019) Samantha N. McNulty et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA
- (2019) Julianna G. Supplee et al. LUNG CANCER
- Investors keep the faith in cancer liquid biopsies
- (2019) Cormac Sheridan NATURE BIOTECHNOLOGY
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
- (2019) Aparna R. Parikh et al. NATURE MEDICINE
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
- (2019) Pedram Razavi et al. NATURE MEDICINE
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
- (2019) Seyed Pairawan et al. CLINICAL CANCER RESEARCH
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
- (2018) Jason D. Merker et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2018) J Mateo et al. ANNALS OF ONCOLOGY
- Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
- (2018) Suresh S. Ramalingam et al. CANCER RESEARCH
- Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting
- (2018) Carolyn J. Presley et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
- (2018) J Zugazagoitia et al. ANNALS OF ONCOLOGY
- Current and future perspectives of liquid biopsies in genomics-driven oncology
- (2018) Ellen Heitzer et al. NATURE REVIEWS GENETICS
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer
- (2018) Charu Aggarwal et al. JAMA Oncology
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
- (2017) Diana Mandelker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer:18F-FDG PET/CT Study
- (2017) Silvia Morbelli et al. JOURNAL OF NUCLEAR MEDICINE
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
- (2017) Aadel A. Chaudhuri et al. Cancer Discovery
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated digital error suppression for improved detection of circulating tumor DNA
- (2016) Aaron M Newman et al. NATURE BIOTECHNOLOGY
- FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
- (2016) Ronglai Shen et al. NUCLEIC ACIDS RESEARCH
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- (2016) Jacob J. Chabon et al. Nature Communications
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
- (2015) C. P. Paweletz et al. CLINICAL CANCER RESEARCH
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
- (2015) Niki Karachaliou et al. JAMA Oncology
- Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma
- (2015) Salim Kanoun et al. PLoS One
- Non–Small Cell Lung Cancer and Precision Medicine
- (2014) Boris Pasche et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress
- (2012) Kevin S. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
- (2009) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started